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Purpose: Pulmonary vein isolation (PVI) is an established approach to treat symptomatic 
non-permanent atrial fibrillation (AF). Detecting AF recurrence after PVI is important, if 
discontinuation of oral anticoagulation after ablation is considered.
Methods: Patients with symptomatic paroxysmal AF were enrolled in the prospective 
randomized mesh ablator vs. cryoballoon pulmonary vein (PV) ablation of symptomatic 
paroxysmal AF study, comparing efficacy and safety of the HD Mesh Ablator® (C.R. 
Bard, Lowell, MA, USA) and the Arctic Front® (Medtronic, Minneapolis, MN, USA) cathe-
ter. Rhythm status post-PVI was closely monitored for 1 year using the implantable loop 
recorder (ILR) Reveal XT® (Medtronic Minneapolis, MN, USA).
results: The study was terminated after the first interim analysis due to the inability of 
the HD Mesh Ablator® to achieve the predefined primary study endpoint, an exit block 
of all PVs. After a 90-day blanking period, 23 (62.2%) out of 37 study patients (median 
63.0 years; 41% females) had at least one episode of AF. AF recurrence was associated 
with AF episodes during the blanking period {hazard ratios (HR) 5.10 [95% confidence 
interval (CI) 1.21–21.4]; p =  0.038}, and a common left-sided PV ostium [HR 4.17 
(95%CI 1.48–11.8); p = 0.039] but not with catheter type, age, gender, cardiovascular 
risk profile, or left atrial volume. There was a trend toward AF recurrence in patients 
without complete PVI of all PV (p = 0.095). Overall, 337 (59.4%) out of 566 ILR-detected 
episodes represented AF. Comparing patients with AF recurrence to those without, there 
was no difference in cognitive performance 6 months post-ablation.
Abbreviations: AF, atrial fibrillation; EF, ejection fraction; LA, left atrial; LV, left ventricular; MACPAF study, mesh ablator 
vs. cryoballoon pulmonary vein ablation of symptomatic paroxysmal atrial fibrillation study; PV(s), pulmonary vein(s); SR, 
sinus rhythm.
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inTrODUcTiOn
Atrial fibrillation (AF) increases stroke risk, impacts quality of 
life, and is associated with cognitive decline (1–3). Pulmonary 
vein isolation (PVI) is now an established therapeutic approach 
in patients with symptomatic paroxysmal or persistent AF (2). 
Besides reducing AF-related symptoms, ablation of pulmonary 
vein (PV) significantly improves quality of life (4).
The ability of PVI to assure continuous sinus rhythm (SR) on 
the long term is limited (5–7) but can be improved by repetitive 
ablation procedures. Reported “success rates” in AF patients 
strictly depend on AF type, patient characteristics, ablation tech-
niques, and the extent of ECG recording after ablation (8–10). 
The implantable loop recorder (ILR) Reveal XT® (Medtronic, 
Minneapolis, MN, USA) is a promising tool to monitor AF recur-
rence by detecting paroxysmal AF with a sensitivity of 96% and 
specificity of 85% (11), and it is more precise to detect AF recur-
rence after PVI compared to repetitive Holter monitoring (9). 
Assessment of AF recurrence is of paramount importance in AF 
patients with low or intermediate stroke risk if discontinuation of 
oral anticoagulation is considered (12). Moreover, AF recurrence 
is important to establish the (technical) efficacy and anatomical 
limitations of new (especially single shot) devices (13).
By implanting the ILR Reveal XT® before PVI within the ran-
domized “mesh ablator vs. cryoballoon pulmonary vein ablation 
of symptomatic paroxysmal atrial fibrillation” (MACPAF) study, 
we aimed to evaluate whether the cryoballoon Arctic Front® 
(Medtronic, Minneapolis, MN, USA) or the radiofrequency-
based HD Mesh Ablator® catheter (C.R. Bard, Lowell, MA, USA) 
is able to achieve continuous SR after a single PVI procedure (14). 
As reported previously, the Arctic Front® catheter proved to be 
superior by achieving a bidirectional block, entrance, and “exit 
block” (EB) of all PVs (15). We here report the ILR data during 
a 12-month follow-up as well as the impact of AF recurrence on 
cognitive performance.
MaTerials anD MeThODs
study Design and study Population
The design of the MACPAF study was previously reported in 
detail (14, 15). In short, the study’s safety board terminated the 
study prematurely due to the inability of the HD Mesh Ablator® 
to achieve the predefined primary study endpoint, an EB of all 
PVs. Of the intended 108 patients with symptomatic paroxysmal 
AF (with prior ineffective antiarrhythmic drug treatment, no 
previous PVI, no unstable structural heart disease), 37 patients 
were randomized for Arctic Front® or HD Mesh Ablator® catheter 
ablation. The balloon shaped catheter Arctic Front® (Medtronic, 
Inc.) uses cryoenergy, whereas the basket shaped catheter device 
HD Mesh Ablator® (C.R. Bard, Inc.) is based on unique pulsed 
radiofrequency delivery. In addition, the latter provides the possi-
bility of circumferential mapping, leading to a reduced procedure 
duration as well as a reduced fluoroscopy time (16).
Study patients underwent PV ablation according to study cri-
teria and were followed up 3, 6, 9, and 12 months afterward. Stable 
cardiac conditions were ensured before ablation by performing 
echocardiography, cardiovascular stress test, and (if indicated) 
coronary angiography. Using MRI or CT datasets, the LA-PVs 
were segmented to generate 3D LA-PV surface reconstructions. 
In MACPAF, PV ostial and antral regions were evaluated. A 
common left-sided ostium was defined as a common ostial 
circumference with left PVs branching >3  mm away from the 
common ostium (17).
A comprehensive cognitive testing was carried out before PVI 
and during the 6  months visit (18), including verbal and non-
verbal learning (Rey–Osterrieth complex figure test and the Rey 
Auditory Verbal Learning Test), short term memory (forward 
digit-span task), attention and executive function (trail-making 
test A and B, Stroop test, category and letter fluency, digit-span 
backward), and reasoning (German Leistungsprüfsystem 50). 
The ILR Reveal XT® (Medtronic Minneapolis, MN, USA) was 
implanted after enrollment in 33 (89%) out of 37 study patients 
to assess AF recurrence after ablation.
analysis of ecg Data
Atrial fibrillation was defined as absolute arrhythmia without 
distinguishable P waves lasting longer than 30 s. AF recurrence 
post-ablation was defined as one AF episode after a 90-day 
blanking period, verified by a board-certified cardiologist (LK, 
AS) blinded for patient reported symptoms during follow-up. 
Rhythm status was monitored using the ILR Reveal XT® (n = 31) 
or repetitive Holter recordings for at least 24 h (range 1–7 days; 
n = 6), respectively. The subcutaneously inserted Reveal XT® is 
able to store up to 49.5 min of automatically or patient activated 
ECG recording. Holter recording and Reveal XT® data down-
load were scheduled on the 3, 6, 9, and 12  months visit. The 
duration of available ECG recording was defined as time from 
first recording of the ILR to the scheduled read-out. AF burden 
was defined as total duration of all verified AF episodes during 
ECG recording.
statistical analysis
For categorical traits, absolute and relative frequencies were com-
puted. In the case of continuous or quasi-continuous variables 
conclusion: Using an ILR, in more than 60% of all patients with paroxysmal AF, a recur-
rence of AF was detected within 12 months after ablation. In patients with a common PV 
ostium, the first generation balloon-based catheter is obviously less effective.
clinical trials: http://Clinicaltrials.gov NCT01061931.
Keywords: catheter ablation, pulmonary veins, atrial fibrillation, arctic Front®, hD Mesh ablator®, ecg monitoring
TaBle 1 | Predictors of atrial fibrillation (aF) recurrence in patients with 
paroxysmal aF within 90 and 365 days after ablation.
aF recurrence
no (n = 14) Yes (n = 23) p
Age; years; median (IQRa) 63.5 
(57.0–69.8)
63.0 
(57.0–67.0)
0.544
Gender; female; % (n) 42.9 (6) 39.1 (9) 0.793
CHA2DS2-VASc; median (IQR) 2.0 (1.0–3.3) 2.0 (1.0–2.0) 0.191
Comorbidities; % (n)
None (“lone” AF) 42.9 (6) 43.5 (10) 0.544
Heart failure 0 (0) 4.3 (1) 0.904
Arterial hypertension 57.1 (8) 52.2 (12) 0.320
Diabetes mellitus 14.3 (2) 13.0 (3) 0.561
Previous stroke 14.3 (2) 4.3 (1) 0.318
Coronary artery disease 28.6 (4) 17.4 (4) 0.381
LV-EFb; %; median (IQR) 67.5 
(64.8–70.0)
65.0 
(60.0–70.0)
0.182
Left atrial volume; ml; median (IQR) 77.8 
(61.9–101.5)
96.7 
(70.4–108.3)
0.304
Creatinine; μmol/l; median (IQR) 84.4 
(72.7–96.4)
78.7 
(69.8–90.2)
0.884
Pulmonary vein (PV) anatomy; % (n)
Common left-sided ostium 0 (0) 21.7 (5) 0.007
Accessory right PV 7.1 (1) 13.0 (3) 0.801
Use of HD Mesh Ablator®; % (n) 35.7 (5) 43.5 (10) 0.549
Use of Arctic Front®; % (n) 65.3 (9) 56.5 (13) 0.549
Exit block of all PVs; % (n) 57.1 (8) 30.4 (7) 0.095
Isolated PVs/patient; n; median (IQR) 4.0 (1.5–4.0) 2.0 (0.0–4.0) 0.062
Procedure duration; min; median (IQR) 209.0 
(188.3–275.0)
206.0 
(192.0–230.0)
0.936
AF recurrence within 90 days post-
pulmonary vein isolation
5 (22.7) 17 (77.3) 0.038
The bold text indicates statistical significance.
aInterquartile range.
bLeft ventricular ejection fraction.
3
Schirdewan et al. Long-term Results of the MACPAF Study
Frontiers in Cardiovascular Medicine | www.frontiersin.org February 2017 | Volume 4 | Article 4
with nearly symmetric distribution, the arithmetic mean, SD, 
minimal and maximal values, otherwise median, quartiles as well 
as minimal and maximal values were computed. Fisher’s exact 
test was used to compare proportions for dichotomous outcomes 
between independent groups or to test independency of two 
dichotomous traits within a population. The Mann–Whitney U 
test was applied to analyze not normally distributed variables. In 
order to analyze predictors of AF recurrence, AF-free survival 
time was computed. Univariate Cox proportional hazards analysis 
and log-rank test (Mantel Cox) were used for outcome analyses of 
AF-free survival. Hazard ratios (HR) and 95% confidence inter-
vals (CI) are presented. The survival function was estimated by 
the Kaplan–Meier method (product-limit estimator). Due to the 
limited number of patients, all statistical tests have to be regarded 
as explorative. p-Values (significance level 0.05) are not adjusted 
for multiple testing.
resUlTs
Patients’ Baseline characteristics
The baseline data of the 37 study patients can be found in the 
Supplementary Material. In short, median age was 63.0  years 
(IQR 56.5–68.0), 40.5% were females and the median CHA2DS2-
VASc score was 2.0 (IQR 1.0–3.0). All patients were available for 
the follow-up after 180 days; one (2.7%) patient with persisting SR 
was lost to follow-up afterward. No patient reported a clinically 
evident ischemic stroke or transient ischemic attack within 1 year 
post-PVI.
assessment of rhythm status and aF 
recurrence during Follow-up
Due to local infection in two (5.4%) of 33 patients, these ILRs had 
to be explanted 19 and 35 days after implantation, respectively. 
Therefore, overall six (16.2%) study patients underwent serial 
Holter–ECG monitoring [median duration 5.0 days (IQR 1.0–5.0, 
range 1–7)] during the 1-year follow-up. After the blanking period 
of 90 days, 23 (62.2%) study patients had an ECG documented 
episode of AF within the next 270 days. In these 23 patients, the 
first documented AF episode occurred within 90 and 179 days 
in 17 (73.9%) patients, within 180 and 269  days in 5 (21.7%), 
and within 270 and 365 days in 1 patient (4.3%). AF recurrence 
was detected in 21 patients by using the ILR and in 2 patients by 
Holter monitoring. Within 90 days post-PVI, 22 (59.5%) of 37 
study patients had at least 1 episode of AF. Five (22.7%) of these 
22 study patients had documented AF only during the 90-day 
blanking period and were therefore considered to have continu-
ous SR. Of all 23 study patients with recurrent AF, 13 (56.5%) 
underwent re-ablation within 1 year after first PVI.
Predictors of aF recurrence
There was no difference regarding age, sex, or cardiovascular 
risk profile in patients with or without AF recurrence within 
3–12  months post-PVI (Table  1). In addition, there was no 
impact of absence of any cardiovascular risk factor (“lone AF”) on 
AF recurrence. However, study patients with a common left-sided 
PV ostium were significantly more liable to suffer AF recurrence 
[HR 4.17 (95%CI 1.48–11.8); p = 0.039]. According to Kaplan–
Meier analysis, AF-free survival is not related to the used catheter 
type (p = 0.547; Figure 1). There was a non-significant trend for 
patients with an EB of all PVs to be in continuous SR at 1-year 
follow-up [HR 0.46 (95%CI 0.19–1.14); p = 0.095] (Table 1). AF 
recurrence within the 90-day blanking period was significantly 
associated with AF recurrence during 90 and 365 days [Table 1; 
HR 5.10 (95%CI 1.21–21.4); p = 0.038].
reliability of aF Detection according to 
the ilr reveal XT®
The ILR Reveal XT® stored a median of 15.0 (IQR 6.0–63.0; range 
1–1,040) episodes of suspected AF per patient and follow-up visit. 
Median duration of assessable ECG monitoring was 48.1  days 
(IQR 14.9–84.2) per follow-up. According to the algorithm 
of the ILR (11), a median AF burden of 0.55% (IQR 0.1–4.8) 
was present in the automated analysis. Overall, 337 (59.4%) of 
566 episodes recorded by the ILR were verified as AF by the 
involved cardiologists. Frequent premature beats, under and 
oversensing of R waves, and a high electrical noise factor caused 
misclassification in the remaining episodes. A median of 9.0 (IQR 
4.0–10.0) AF episodes per patient and follow-up was validated. 
Median duration of assessable Holter monitoring was 48.1 days 
FigUre 1 | atrial fibrillation (aF)-free survival after pulmonary vein isolation (PVi) according to (a) achieved exit block of all pulmonary veins (PVs) 
during first PVi (p = 0.086) and (B) used catheter device (p = 0.547).
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(IQR 14.9–84.2) per follow-up. Median burden of verified AF in 
ILR patients was 0.21% (IQR 0–10.0) pre-ablation, 0.0% (IQR 
0–4.5) on day 180, and 0.0% (IQR 0–2.0) on day 365, while 
median burden of automatically detected AF episodes by the 
ILR was 0.50% (IQR 0.1–9.1) pre-ablation, 0.1% (IQR 0.1–3.8) 
on day 180, and 0.2% (IQR 0.1–2.1) on day 365 (Figure 2). The 
Wilcoxon signed-rank test indicated a reduction of the verified 
AF burden (p = 0.05) as well as the automatically detected AF 
burden after 365 days (p = 0.034) compared to the pre-ablation 
period (Figure 2).
symptomatic aF and Medication during 
Follow-up
Atrial fibrillation-related symptoms like palpitations and dizziness 
were reported by 13 (76.5%) of 17 patients with AF recurrence on 
day 180. In addition, 4 (20%) of 20 patients without AF recur-
rence reported similar symptoms on day 180. On day 365, such 
symptoms were reported in 13 (56.5%) of 23 patients with AF 
recurrence and in 3 (23.1%) of 13 patients without (p = 0.083). In 
patients with “symptomatic” AF recurrence, recorded AF burden 
was significantly higher compared to those with “asymptomatic” 
AF recurrence [median 0.2% (IQR 0.08–0.48) vs. median 2.5% 
(IQR 0.55–5.28); p = 0.010].
On 1-year follow-up, 11 (31.4%) of all 36 study patients 
received at least one antiarrhythmic drug (2.9% amiodarone, 
11.4% dronedarone, 17.1% other). Only one (9.1%) out of 13 
patients without AF recurrence still received antiarrhythmic 
drugs. In addition, 27 (77.1%) of 36 patients were on oral antico-
agulation, while 7 (19.4%) received an antiplatelet agent.
impact of aF recurrence on cognitive 
Performance
Neuropsychological testing was carried out in 36 (97%) of 
37 patients during the 6-month follow-up visit. No patient 
complained about cognitive impairment during follow-up. 
Comparing patients with AF recurrence between 90 and 180 days 
to those without revealed no significant differences regarding all 
tested domains (Table 2).
DiscUssiOn
Based on the here reported long-term results of the MACPAF 
study, the following main findings can be drawn from the study: 
using an ILR, 62% of all study patients with paroxysmal AF had 
recurrent AF within 90 days and 1-year post-PVI. AF recurrence 
during the 90-day blanking period was associated with a fivefold 
higher risk of AF recurrence. Patients with a common left-sided 
PV ostium had a fourfold higher risk of AF recurrence after a single 
ablation procedure, indicating that a first generation  balloon- or 
basket-based catheter is less effective in these patients. There was 
no apparent impact of AF recurrence on cognitive performance 
6 months post-PVI as determined by testing attention, executive 
functions, short term memory, verbal and non-verbal learning as 
well as reasoning.
In recent years, multiple innovative technical solutions for left 
atrial catheter ablation of symptomatic AF have been developed 
such as the balloon-based Arctic Front® catheter (using cryoen-
ergy) or the basket-based HD Mesh Ablator® catheter (using 
pulsed radiofrequency), providing the opportunity to induce 
FigUre 2 | Boxplots of (a) automatically detected atrial fibrillation (aF) burden (%) by the implantable loop recorder and (B) computed aF burden of 
verified aF episodes pre-ablation and during follow-up. p values computed by the Wilcoxon signed-rank test (dotted line pre-ablation vs. day 180 post-
ablation and solid line pre-ablation vs. day 365 post-ablation).
TaBle 2 | neuropsychological assessment pre-ablation and 6 months post-ablation according to atrial fibrillation (aF) recurrence.
aF recurrence >90 days post-ablation
no (n = 20/20) Yes (n = 16/17)
Pre-laca Day 180 Pre-laca Day 180 p*
attention and executive functions
Trail-making test A; s 36 (27–47) 38 (29–56) 39 (26–43) 30 (25–43) 0.262
Trail-making test B; s 89 (77–129) 84 (67–120) 74 (65–102) 67 (60–108) 0.149
Color–word-interference test (Stroop); s 153 (141–182) 136 (125–172) 156 (135–160) 124 (105–142) 0.077
Category fluency; n 24 (18–30) 26 (21–31) 26 (21–31) 28 (24–30) 0.888
Letter fluency; n 17 (11–19) 14 (9–22) 17 (11–19) 17 (15–20) 0.286
Digit-span backward; points 8 (7–9) 8 (6–9) 8 (7–10) 9 (8–11) 0.189
short-term memory
Digit-span forward; points 6 (5–7) 6 (5–8) 7 (6–10) 9 (6–11) 0.369
learning (verbal and non-verbal)
RAVLTa; n 1 (−1 to 3) 9 (8–11) 0 (−3 to 5) 10 (7–11) 0.832
ROC figureb; points 23 (20–27) 26 (24–28) 30 (25–32) 27 (26–32) 0.779
reasoning
LPS 50c; points 21 (16–24) 21 (17–25) 23 (20–26) 3 (0–4) 0.236
*p values based on exact Mann–Whitney test.
aRey Auditory Verbal Learning Test (German Version); delayed recall (A7).
bRey–Osterrieth complex figure; immediate recall.
cSubtest 3 from the German Leistungsprüfsystem (LPS).
Values are expressed as median (IQR).
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circumferential scars around the PV ostia (antral aspect) (19). 
However, the missing ability of the investigated first generation 
devices to do focal ablation is of practical importance regard-
ing efficacy. The limited device efficacy and the relatively small 
patient cohort may explain the missing statistical significance 
regarding AF-free survival which was observed in other studies 
(20). A statistical trend toward less AF recurrences in patients 
with EB of all PVs further supports that transmural permanent 
PVI is an important factor of long-term success.
While these first generation devices obviously did not fit to all 
distinct PV anatomies, a substantial proportion of patients with 
paroxysmal AF suffered from mostly asymptomatic AF recur-
rences after PVI (21–23), and MACPAF patients with a common 
left-sided PV ostium were four times more liable to suffer AF 
recurrence [HR 4.17 (95%CI 1.48–11.8)]. Our results confirm an 
early prediction by Ahmed et al. that—based on the analysis of 
3D surface reconstructions of LA-PV anatomy from MRI datasets 
in 101 patients—balloon or basket catheter-based ablation of the 
6Schirdewan et al. Long-term Results of the MACPAF Study
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common PV antra would be problematic (17). This anatomical 
variant was found in 14% of all MACPAF patients compared to 
a prevalence of 2–7% in other ablation cohorts. This probably 
explains the missing association with AF recurrence in studies 
using similar ablation catheters (16, 24).
Analyzing the high rate of AF recurrence, the achieved 
results by the first generation cryoballoon are comparable to 
radiofrequency systems. The improved engineering of the second- 
generation cryoballoon leads to substantially higher efficacy also 
in patients with anatomical PV variants (25, 26). On the other 
hand, the inefficacy of the basket-based Mesh catheter raised 
serious concerns regarding the underlying technical concept.
Confirming previous studies (27, 28), patients with AF recur-
rence during the (well established) 90-day blanking period had 
a fivefold higher risk for later AF recurrence. However, about 
23% of all study patients had documented AF only during the 
90-day blanking period and were considered to have persisting 
SR after PVI. This finding is not in line with a previous study on 
35 patients with paroxysmal AF (29), reporting AF recurrence 
in all 13 patients with AF during the blanking period. In conclu-
sion, we do not think that the so-called blanking period loses its 
intrinsic meaning. We suggest that (even asymptomatic) patients 
with documented AF recurrence within 90  days after ablation 
should undergo intense ECG monitoring if the CHA2DS2-VASc 
score is ≥2 and long-term oral anticoagulation—despite current 
guideline recommendations (2, 30, 31)—is not intended.
The method and intensity of rhythm surveillance has become 
a major topic of post-ablational care. As an example, the rand-
omized RAAFT 2 trial demonstrated a recurrence rate of AF/
atrial flutter/atrial tachycardia of 24% by using standard Holter 
ECGs and a recurrence rate of 47% in the 2-year follow-up by 
using an additional transtelephonic monitoring (32). Available 
prospective ILR-studies on AF recurrence after PVI are mostly 
based on single-center experience, report on a limited number of 
AF patients, and are heterogeneous regarding AF type, definition 
of AF recurrence, ablation technique as well as duration of follow-
up (9, 10, 29, 32, 33). Subsequently, there are few comparable data 
to the here reported AF recurrence rate of 62% within 1 year after 
a single balloon-based PVI of symptomatic paroxysmal AF. Using 
a similar definition of AF recurrence, Pedrote et al. reported an 
AF recurrence in 43% of 35 patients with paroxysmal AF within 
1  year after a single PVI using radiofrequency (29). A recent 
propensity score-matched comparison of radiofrequency or cry-
oballoon ablation in 142 patients with paroxysmal AF reported 
similar long-term recurrence rates of 44 or 52% after a single 
ablation procedure, respectively (34). By using a threshold of 
“percentage of time spent in AF <0.5%” for considering a patient 
“free” of AF, a recurrence rate of 32% was reported for similar 
cohorts of patients with paroxysmal AF undergoing a single 
ablation procedure using radiofrequency (10, 33). In this context, 
the feasibility of discontinuation of oral anticoagulation within 
months post-PVI in AF patients with at least moderate stroke 
risk remains disputable.
While the use of ILRs is feasible (9, 10, 21, 29, 33) and 
more effective compared to repetitive Holter monitoring (9), 
automated recording of AF by the ILR Reveal XT® is prone to 
false positive results (9). Our data revealed that about 60% of the 
ILR-detected “AF”-episodes could be verified by board-certified 
cardiologists. As similarly reported by Kapa et al. (9), main causes 
of false-positive AF detection by the ILR were frequent atrial and 
ventricular extrasystoles, undersensing of R waves, oversens-
ing of R and T waves, and a high electrical noise factor. ILR 
misclassification (41% false-positive) was comparable to Kapa 
et al. [54% false-positive (9)] and Eitel et al. [38% false-positive 
(35)] but higher compared to Schmidt et al. [26% false-positive 
(36)]. While adjusting of the diagnostic algorithm has previously 
proven to improve specificity (35), further improvements are 
needed. Despite of being technically outdated by the Reveal 
LINQ®, socioeconomic reasons are likely to lead to an ongoing 
use of the Reveal XT®. Next to establishing continuous SR, con-
trol of AF-related symptoms is the main goal of ablation therapy. 
In our cohort, 43% of patients with AF recurrence reported to 
be free of AF-related symptoms after 12  months. AF burden 
was significantly reduced in those patients after a single ablation 
procedure, confirming the concept of single shot devices in prin-
ciple. This confirms previous studies reporting a reduced rate of 
symptomatic AF and an improved quality of life even in ablated 
patients without continuous SR (4, 23).
In addition to AF-related symptoms, cognitive decline has 
been reported in AF patients (3, 37, 38) as well as in AF patients 
post-ablation (39). Whether continuous SR post-AF ablation 
might have a positive impact on cognitive function has not yet 
been reported. Our results demonstrate that rhythm status had 
no significant impact on cognitive function over a period of 
180 days after ablation. However, large prospective multicenter 
studies are warranted to clarify this matter.
The study has several strengths but also limitations. While the 
study design is unique, the premature termination of the study 
limits the significance of the reported results. Subsequently, we 
cannot definitively prove that there was no impact of the absence 
of any cardiovascular risk factor (“lone AF”) on AF recurrence. 
In addition, PVI-related parameters such as procedure duration 
or the used catheter type in this randomized study had no impact 
on AF recurrence, despite of the fact that the HD Mesh Ablator® 
catheter was inferior to the Arctic Front® catheter in achieving 
an EB of all PVs (15). Furthermore, MACPAF results cannot be 
generalized to patients with persistent AF or distinct catheter 
types. In addition, the vast majority but not all patients were 
monitored by an ILR, and one patient was lost to follow-up after 
the 6 months visit.
However, the MACPAF results deliver relevant insights into 
important practical aspects of ILR-based follow-up performance. 
Moreover, our findings indicate that first generation balloon-
based devices should not be used in patients with a common PV 
ostium.
cOnclUsiOn
Using an ILR in 62% of all study patients with paroxysmal AF 
a recurrence of AF was detected within 90 days and 12 months 
after a single balloon-based ablation procedure. While AF bur-
den was diminished after a single ablation procedure in general, 
about one third of patients with AF recurrence still suffered from 
symptomatic AF. Detected AF recurrence during the blanking 
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period of 90 days post-ablation renders later AF recurrence five-
fold more likely. A common left-sided PV ostium was associated 
with a fourfold higher risk of AF recurrence, indicating that a 
single balloon-based ablation procedure is less effective in these 
patients. Despite the fact that AF recurrence post-ablation had 
no significant impact on cognitive function 6 months after PVI, 
our study clearly demonstrates that intensive screening for AF 
recurrence after ablation is of major importance.
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